Completed PHASE3 INTERVENTIONAL NCT00034268

A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Conditions Carcinoma, Non-Small-Cell Lung

Interventions LY900003

Updated 6 times since 2017 Last updated: Jul 18, 2006 Started: Mar 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00034268, this PHASE3 trial focuses on Carcinoma, Non-Small-Cell Lung and remains completed. Sponsored by Eli Lilly and Company, it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Abingdon, United States , Alicante, Spain , Amsterdam, Netherlands , Arcadia, South Africa , Arlington, United States , Arnhem, Netherlands , Augsburg, Germany , Badalona, Spain , Baltimore, United States and 95 more locations